$ATRA
Atara Biotherapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024037644 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $27.36M $4.252M $8.573M
YoY Change 2131.4% 1823.98% -86.51%
Cost Of Revenue $1.985M $3.160M $8.886M
YoY Change 818.98%
Gross Profit $25.37M $1.092M -$313.0K
YoY Change 2412.08%
Gross Profit Margin 92.74% 25.68% -3.65%
Selling, General & Admin $9.756M $10.39M $49.80M
YoY Change -29.44% -20.12% -26.91%
% of Gross Profit 38.45% 951.28%
Research & Development $45.51M $43.98M $219.2M
YoY Change -26.79% -29.83% -18.82%
% of Gross Profit 179.36% 4027.56%
Depreciation & Amortization $900.0K $1.209M $4.829M
YoY Change 0.0% -3.67% -14.58%
% of Gross Profit 3.55% 110.71%
Operating Expenses $45.51M $54.37M $269.0M
YoY Change -40.32% -28.17% -20.45%
Operating Profit -$31.25M -$53.28M -$269.3M
YoY Change -58.35% -4.01%
Interest Expense $1.153M -$465.0K $141.0K
YoY Change -13.7% -147.99% -92.9%
% of Operating Profit
Other Income/Expense, Net $68.00K -$12.00K -$246.0K
YoY Change -134.52% -64.86%
Pretax Income -$31.73M -$60.44M -$276.1M
YoY Change -57.55% -18.95% 20.95%
Income Tax $24.00K $11.00K $15.00K
% Of Pretax Income
Net Earnings -$31.75M -$60.45M -$276.1M
YoY Change -57.53% -18.94% 20.95%
Net Earnings / Revenue -116.07% -1421.68% -3220.88%
Basic Earnings Per Share -$0.23 -$2.61
Diluted Earnings Per Share -$0.23 -$0.56 -$2.61
COMMON SHARES
Basic Shares Outstanding 119.4M 101.9M 105.9M
Diluted Shares Outstanding 140.6M 105.9M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.24M $51.73M $51.73M
YoY Change -77.49% -78.7% -78.7%
Cash & Equivalents $35.09M $25.84M $25.84M
Short-Term Investments $11.15M $25.88M $25.88M
Other Short-Term Assets $8.131M $6.330M $6.330M
YoY Change -36.93% -38.59% -39.45%
Inventory $16.08M $9.706M $9.706M
Prepaid Expenses
Receivables $35.83M $34.11M $34.11M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $106.4M $101.9M $101.9M
YoY Change -52.52% -65.48% -65.48%
LONG-TERM ASSETS
Property, Plant & Equipment $2.989M $58.79M $58.79M
YoY Change -48.92% -20.9% -20.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.868M $4.844M $4.844M
YoY Change -43.99% -30.98% -30.98%
Total Long-Term Assets $58.84M $63.64M $63.64M
YoY Change -24.47% -21.77% -21.77%
TOTAL ASSETS
Total Short-Term Assets $106.4M $101.9M $101.9M
Total Long-Term Assets $58.84M $63.64M $63.64M
Total Assets $165.3M $165.5M $165.5M
YoY Change -45.29% -56.03% -56.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.854M $3.684M $3.684M
YoY Change -43.69% -46.38% -46.38%
Accrued Expenses $18.20M $59.79M $59.79M
YoY Change 169.12% -5.41% -5.41%
Deferred Revenue $77.83M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $945.0K $915.0K $915.0K
YoY Change 13.58% 9.71% 9.71%
Total Short-Term Liabilities $180.7M $142.2M $142.2M
YoY Change 166.21% 80.22% 80.22%
LONG-TERM LIABILITIES
Long-Term Debt $35.57M $34.65M $34.65M
YoY Change 851.19% 851.19%
Other Long-Term Liabilities $4.401M $87.86M $87.86M
YoY Change -14.99% -47.46% -47.46%
Total Long-Term Liabilities $4.401M $122.5M $122.5M
YoY Change -14.99% -28.3% -28.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $180.7M $142.2M $142.2M
Total Long-Term Liabilities $4.401M $122.5M $122.5M
Total Liabilities $263.6M $264.7M $264.7M
YoY Change 11.16% 5.99% 5.99%
SHAREHOLDERS EQUITY
Retained Earnings -$2.001B -$1.969B
YoY Change 13.19% 16.31%
Common Stock $1.903B $1.870B
YoY Change 3.74% 2.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$98.31M -$99.23M -$99.23M
YoY Change
Total Liabilities & Shareholders Equity $165.3M $165.5M $165.5M
YoY Change -45.29% -56.03% -56.03%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$31.75M -$60.45M -$276.1M
YoY Change -57.53% -18.94% 20.95%
Depreciation, Depletion And Amortization $900.0K $1.209M $4.829M
YoY Change 0.0% -3.67% -14.58%
Cash From Operating Activities -$29.61M -$50.41M -$193.0M
YoY Change -22.94% -11.38% -28.64%
INVESTING ACTIVITIES
Capital Expenditures $127.0K $43.00K $1.223M
YoY Change -68.17% 16.22% -70.83%
Acquisitions
YoY Change
Other Investing Activities $14.84M $9.989M $125.1M
YoY Change -364.69% -80.51% -39.61%
Cash From Investing Activities $14.72M $9.946M $123.9M
YoY Change -345.0% -80.58% -38.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.136M
YoY Change -90.24%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.14M 1.510M 2.010M
YoY Change 10172.77% -95.32% -96.21%
NET CHANGE
Cash From Operating Activities -29.61M -50.41M -193.0M
Cash From Investing Activities 14.72M 9.946M 123.9M
Cash From Financing Activities 24.14M 1.510M 2.010M
Net Change In Cash 9.246M -38.95M -67.10M
YoY Change -120.92% -246.28% 366.3%
FREE CASH FLOW
Cash From Operating Activities -$29.61M -$50.41M -$193.0M
Capital Expenditures $127.0K $43.00K $1.223M
Free Cash Flow -$29.74M -$50.45M -$194.2M
YoY Change -23.41% -11.36% -29.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001604464
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36548
CY2023 dei Entity Registrant Name
EntityRegistrantName
ATARA BIOTHERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0920988
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2380 Conejo Spectrum Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Thousand Oaks
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91320
CY2023 dei City Area Code
CityAreaCode
805
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6871000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11519000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17659000
CY2023Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
17364000
CY2023 dei Local Phone Number
LocalPhoneNumber
623-4211
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
ATRA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
161602451
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119359230
CY2023 dei Auditor Firm
AuditorFirmId
34
CY2023 dei Auditor Name
AuditorName
DELOITTE & TOUCHE LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25841000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
25884000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
149877000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34108000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40221000
CY2023Q4 us-gaap Inventory Net
InventoryNet
9706000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6184000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10308000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
101869000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295080000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3856000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54935000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68022000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4844000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7018000
CY2023Q4 us-gaap Assets
Assets
165504000
CY2022Q4 us-gaap Assets
Assets
376420000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3684000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
272533000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50908000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
71553000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
284579000
CY2022Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24992000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
77833000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
8000000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31826000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
142226000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78916000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37562000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77000000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45693000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58064000
CY2023Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
34623000
CY2022Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
30236000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4631000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5564000
CY2023Q4 us-gaap Liabilities
Liabilities
264735000
CY2022Q4 us-gaap Liabilities
Liabilities
249780000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106447000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106447000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95927000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95927000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1870112000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1821721000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-204000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2067000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1969150000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1693024000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99231000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165504000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
376420000
CY2023 atra Commercialization Revenue
CommercializationRevenue
7886000
CY2022 atra Commercialization Revenue
CommercializationRevenue
0
CY2023 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
687000
CY2022 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
63573000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8573000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
63573000
CY2023 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
8886000
CY2022 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
0
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
224785000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
344086000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-276006000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-280513000
CY2023 us-gaap Interest Income Operating
InterestIncomeOperating
5426000
CY2022 us-gaap Interest Income Operating
InterestIncomeOperating
3059000
CY2023 us-gaap Interest Expense
InterestExpense
5285000
CY2022 us-gaap Interest Expense
InterestExpense
373000
CY2023 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
CY2022 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
50237000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-246000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-700000
CY2023 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
-105000
CY2022 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
52223000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-276111000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-228290000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-276126000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-228302000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1863000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1699000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-274263000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-230001000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.61
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.61
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105912000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105912000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101990000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101990000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279614000
CY2022 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
21891000
CY2022 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
623000
CY2022 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1921000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
53838000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-228302000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1699000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
2172000
CY2023 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
94000
CY2023 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
928000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
45386000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-276126000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1863000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99231000
CY2023 us-gaap Profit Loss
ProfitLoss
-276126000
CY2022 us-gaap Profit Loss
ProfitLoss
-228302000
CY2023 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
0
CY2022 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
50237000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
45386000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
53838000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4829000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5653000
CY2023 us-gaap Accretion Expense
AccretionExpense
4792000
CY2022 us-gaap Accretion Expense
AccretionExpense
0
CY2023 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
11795000
CY2022 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
8915000
CY2023 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-792000
CY2022 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1024000
CY2023 atra Other Non Cash Items Net
OtherNonCashItemsNet
214000
CY2022 atra Other Non Cash Items Net
OtherNonCashItemsNet
147000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6113000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
39235000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8120000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1586000
CY2023 atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
-273000
CY2022 atra Increase Decrease In Other Current Asset
IncreaseDecreaseInOtherCurrentAsset
-1836000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1043000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
266000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3130000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9211000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-6140000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7491000
CY2023 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-3663000
CY2022 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
11541000
CY2023 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
11064000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2067000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
30395000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11468000
CY2023 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-12636000
CY2022 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-8009000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
142000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
354000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-192977000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-270430000
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
83648000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
180589000
CY2023 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
208712000
CY2022 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
292973000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1223000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4193000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
CY2022 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
94765000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
123866000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
202956000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2136000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21891000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
928000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1921000
CY2023 atra Proceeds From Sale Of Future Royalties Net
ProceedsFromSaleOfFutureRoyaltiesNet
0
CY2022 atra Proceeds From Sale Of Future Royalties Net
ProceedsFromSaleOfFutureRoyaltiesNet
30605000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
94000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
623000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
947000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
518000
CY2023 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-13000
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-192000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2010000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53084000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-67101000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14390000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107478000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25987000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
132000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
61000
CY2023 atra Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
78000
CY2022 atra Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
0
CY2023 atra Proceeds From Issuance Of Common Stock Through Atm Facilities Not Yet Received
ProceedsFromIssuanceOfCommonStockThroughAtmFacilitiesNotYetReceived
114000
CY2022 atra Proceeds From Issuance Of Common Stock Through Atm Facilities Not Yet Received
ProceedsFromIssuanceOfCommonStockThroughAtmFacilitiesNotYetReceived
0
CY2023 atra Non Cash Investing And Financing Activities Accrued Transaction Costs Related To Sale Of Future Royalties
NonCashInvestingAndFinancingActivitiesAccruedTransactionCostsRelatedToSaleOfFutureRoyalties
0
CY2022 atra Non Cash Investing And Financing Activities Accrued Transaction Costs Related To Sale Of Future Royalties
NonCashInvestingAndFinancingActivitiesAccruedTransactionCostsRelatedToSaleOfFutureRoyalties
332000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
447000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
335000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
100000000
CY2023Q4 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.30
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6700000
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
63600000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Significant estimates and assumptions relied upon in preparing these financial statements include those related to revenue recognition, accrued research and development expenses, stock-based compensation expense, liability related to the sale of future revenues and income taxes. Additionally, we use available market information to assess the fair value of our short-term investments. Actual results could differ materially from those estimates. If actual amounts differ from estimates, we include the updates in our consolidated results of operations in the period the actual amounts become known. Historically, the aggregate differences, if any, between our estimates and actual amounts in any year have not had a material effect on our consolidated financial statements.</span></p>
CY2023 atra Going Concern Policy Textblock
GoingConcernPolicyTextblock
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred operating losses since inception and we expect that existing cash, cash equivalents and short-term investments as of December 31, 2023, will not be sufficient to fund our planned operations for at least 12 months after the issuance of the accompanying consolidated financial statements. Although we anticipate the receipt of certain payments from the amended and restated Pierre Fabre Commercialization Agreement in 2024 and 2025, such payments are contingent upon the successful filing and approval of the tab-cel BLA, as well as the completion of specific development and regulatory activities by us and actions taken by third parties, and are, therefore, uncertain at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, we plan to secure additional capital, potentially through a combination of public or private security offerings; use of our ATM facility as described in Note 9; and/or strategic transactions. We may also need to raise additional funding as required based on the status of our development programs and our projected cash flows. Although we have been successful in raising capital in the past, and expect to continue to raise capital as required, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. If we are unable to obtain sufficient funding on acceptable terms, we could be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates, which could have a material adverse effect on our business, results of operations, and financial condition. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds; U.S. Treasury, government agency and corporate debt obligations; commercial paper; certificates of deposit; and asset-backed securities, which can be subject to certain credit risk. We strive to mitigate this credit risk by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.</span></p>
CY2023 atra Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2023 atra Investment Maturity Period
InvestmentMaturityPeriod
P90D
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
300000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
800000
CY2023 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2022 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
401(k)
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2023 atra Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
1900000
CY2022 atra Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
2300000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17153707
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17122274
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
50393000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
50189000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
202323000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
201359000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
36746000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
35643000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
50393000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50189000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
239069000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
237002000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25841000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
146000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
146000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25987000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
85000000
CY2023 us-gaap Deferred Income Addition
DeferredIncomeAddition
38170000
CY2023 us-gaap Deferred Income Revenue Recognized
DeferredIncomeRevenueRecognized
7775000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
115395000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
77833000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37562000
CY2023 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
5000000
CY2022Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
30236000
CY2023 us-gaap Accretion Expense
AccretionExpense
4792000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
79000
CY2023 us-gaap Payments For Royalties
PaymentsForRoyalties
31000
CY2023Q4 atra Liability Related To Sale Of Future Revenues
LiabilityRelatedToSaleOfFutureRevenues
35076000
CY2023Q4 atra Liability Related To The Sale Of Future Revenue Current
LiabilityRelatedToTheSaleOfFutureRevenueCurrent
-453000
CY2023Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
34623000
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
94800000
CY2022Q2 atra Transaction Costs
TransactionCosts
4600000
CY2022 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
50200000
CY2022 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
94765000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Other Current Assets
DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
190000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
44299000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Other Noncurrent Assets
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
39000
CY2022Q4 atra Net Assets Sold
NetAssetsSold
44528000
CY2022 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
50237000
CY2021Q1 atra Lease Option To Extend Additional Term
LeaseOptionToExtendAdditionalTerm
P5Y
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
17209000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1219000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
18486000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
1263000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
17271000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
1285000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5760000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
436000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3319000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12459000
CY2023Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
74504000
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
4203000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17547000
CY2023Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
673000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56957000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
3530000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11264000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
915000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45693000
CY2023Q4 atra Finance Lease Other Long Term Liabilities
FinanceLeaseOtherLongTermLiabilities
2615000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56957000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
3530000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
17192000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
14245000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
201000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
386000
CY2023 atra Operating Lease Cost Including Short Term Lease
OperatingLeaseCostIncludingShortTermLease
17393000
CY2022 atra Operating Lease Cost Including Short Term Lease
OperatingLeaseCostIncludingShortTermLease
14631000
CY2023 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
976000
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
872000
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
416000
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
373000
CY2023 atra Finance Lease Cost
FinanceLeaseCost
1392000
CY2022 atra Finance Lease Cost
FinanceLeaseCost
1245000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
16660000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
13417000
CY2023 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
416000
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
335000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
947000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
518000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
312000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
50779000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
4795000
CY2023 atra Non Cash Increase To Operating Lease Assets Due To Remeasurement Of Lease Liabilities
NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities
-1589000
CY2022 atra Non Cash Increase To Operating Lease Assets Due To Remeasurement Of Lease Liabilities
NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities
0
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.114
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.104
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.104
CY2022Q3 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.20
CY2022Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6000000
CY2023Q4 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.30
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6700000
CY2023 us-gaap Restructuring Charges
RestructuringCharges
6730000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
5964000
CY2023Q4 atra Accrued Expense Restructuring
AccruedExpenseRestructuring
4900000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1545000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023 us-gaap Restructuring Charges
RestructuringCharges
6730000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
5964000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
3352000
CY2022 us-gaap Payments For Restructuring
PaymentsForRestructuring
4419000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
4923000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1545000
CY2023Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2023Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2022Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q4 atra Recorded Unconditional Service Obligations Due Within One Year
RecordedUnconditionalServiceObligationsDueWithinOneYear
14085000
CY2023Q4 atra Recorded Unconditional Service Obligation Due In Second Year
RecordedUnconditionalServiceObligationDueInSecondYear
13308000
CY2023Q4 atra Recorded Unconditional Service Obligations Due Within Third Year
RecordedUnconditionalServiceObligationsDueWithinThirdYear
9605000
CY2023Q4 atra Recorded Unconditional Service Obligations Due In Fourth Year
RecordedUnconditionalServiceObligationsDueInFourthYear
3388000
CY2023Q4 atra Recorded Unconditional Service Obligation
RecordedUnconditionalServiceObligation
40386000
CY2023 atra Minimum Commitments Expense
MinimumCommitmentsExpense
19400000
CY2022 atra Minimum Commitments Expense
MinimumCommitmentsExpense
14200000
CY2023Q4 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
11200000
CY2022Q4 atra Minimum Purchase Commitments Accrued
MinimumPurchaseCommitmentsAccrued
9200000
CY2023Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2022Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2023Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 atra Common Stock Value Remained Available To Be Sold
CommonStockValueRemainedAvailableToBeSold
98200000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15989
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2023 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.839
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.732
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.62
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.88
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4693897
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3615971
CY2023 atra Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue
12298010
CY2022 atra Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue
21261909
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
17000000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
23200000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25110096
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45386000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53838000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-276360000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-228395000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
249000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
105000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-276111000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-228290000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
14000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
12000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
15000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.043
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.078
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.045
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.038
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.204
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.248
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
323581000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
302591000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
72229000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
50522000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
30580000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
19427000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
14033000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
19201000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
17018000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
10069000
CY2023Q4 atra Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
12035000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
640000
CY2022Q4 atra Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
15857000
CY2023Q4 atra Deferred Tax Assets License Fees
DeferredTaxAssetsLicenseFees
5926000
CY2022Q4 atra Deferred Tax Assets License Fees
DeferredTaxAssetsLicenseFees
6877000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
11187000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
13169000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
486589000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
437713000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
474982000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
422493000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11607000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15220000
CY2023Q4 atra Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
11607000
CY2022Q4 atra Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
15220000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
11607000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
15220000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 atra Deferred Tax Assets Change In Capitalized Expenses Amount
DeferredTaxAssetsChangeInCapitalizedExpensesAmount
21700000
CY2022 atra Deferred Tax Assets Change In Capitalized Expenses Amount
DeferredTaxAssetsChangeInCapitalizedExpensesAmount
43700000
CY2023 atra Tax Credit Carryforward Change In Amount
TaxCreditCarryforwardChangeInAmount
11200000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
52500000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
1100000000
CY2023Q4 atra Deferred Tax Assets Tax Credit Carry Forwards Orphan Drug
DeferredTaxAssetsTaxCreditCarryForwardsOrphanDrug
111800000
CY2023 atra Deferred Tax Assets Tax Credit Carry Forwards Orphan Drug Expiration Years
DeferredTaxAssetsTaxCreditCarryForwardsOrphanDrugExpirationYears
2035
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
144067000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7683000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
785000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
150965000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
5538000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
3843000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
160346000
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2335000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1214000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
7371000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
372000
CY2023Q4 us-gaap Inventory Net
InventoryNet
9706000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19725000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18722000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15869000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12422000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3856000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023 us-gaap Depreciation
Depreciation
3700000
CY2022 us-gaap Depreciation
Depreciation
4700000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19007000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7435000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11264000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12806000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
915000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
834000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31826000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-037644-index-headers.html Edgar Link pending
0000950170-24-037644-index.html Edgar Link pending
0000950170-24-037644.txt Edgar Link pending
0000950170-24-037644-xbrl.zip Edgar Link pending
atra-20231231.htm Edgar Link pending
atra-20231231.xsd Edgar Link pending
atra-ex10_29.htm Edgar Link pending
atra-ex10_30.htm Edgar Link pending
atra-ex10_31.htm Edgar Link pending
atra-ex21_1.htm Edgar Link pending
atra-ex23_1.htm Edgar Link pending
atra-ex31_1.htm Edgar Link pending
atra-ex31_2.htm Edgar Link pending
atra-ex32_1.htm Edgar Link pending
atra-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img120931721_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
atra-20231231_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending